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Background: Although cough is a commonly reported symptom, objective quantitation of cough during normal activity has not been performed in
patients with CF.
Methods: An ambulatory device was used to characterize cough over 24 hours. Pulmonary function and subject-reported coughing were also
assessed.
Results: Patients included 19 clinically stable adults with CF (males:females=10:9; median age [range]=26 [19-57] years; median %-predicted
FEV1 [range]=65 [44-106]%). Median [range] cough rate was 27 [13-66] coughs/hour, with values while awake of 41 [20-102] and while asleep
of 2 [0.1-7] (pb0.0001, Wilcoxon signed-rank test). Subjective reporting was consistent with objective data for wake-sleep differences, but
correlated poorly with objective waking cough rate.
Conclusions: Outpatient cough quantitation in patients with CF is feasible, indicates frequent coughing even during clinical stability, and may be
useful in therapeutic trials in CF.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Adult; cystic fibrosis; cough; respiratory function tests1. Introduction
Cystic fibrosis (CF) is an autosomal recessive disorder
caused by defects in the gene for the cystic fibrosis
transmembrane conductance regulator (CFTR), a chloride
channel that regulates electrolyte and water transport across
the apical membrane of epithelial cells [1]. In the lung,
disruption of CFTR-mediated chloride transport results in
dehydration of the periciliary fluid layer and viscous respiratory⁎ Corresponding author at: Hadassah Hebrew University Medical Center,
Jerusalem, Israel 91240. Tel.: +972 2 584 4430; fax: +972 2 584 4427.
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doi:10.1016/j.jcf.2011.02.003secretions that lead to airway obstruction, mucus plugging,
bronchiectasis, bacterial infection, and persistent neutrophilic
inflammation [2]. As an important surrogate marker for disease
severity and survival [3,4], forced expiratory volume in 1
second (FEV1) has been the major outcome measure in clinical
trials of therapies for CF [3,5]. However, patients with normal
FEV1 values may have substantial inflammation, obstruction,
and bronchiectasis [6]. Furthermore, FEV1 has not offered a
symptomatic indicator of patient health.
Excessive coughing is a common and distressing adverse
experience [7]. Patients with chronic cough describe frustration,
irritability, and anger relating to disruption of daily activities
and social interactions [7]. In patients with stable CF, cough isd by Elsevier B.V. All rights reserved.
Table 1
Subjective Cough Scoring Questionnaire.
Score Description
Daytime Coughing
1 I almost never have coughing during the day
2 I usually have a few periods of coughing during the day
3 I usually have several periods of coughing during the day
4 I usually have frequent periods of coughing during the day
Nighttime Coughing
1 I almost never wake up because of coughing
2 I usually wake up once per night because of coughing
3 I usually wake up a few times per night because of coughing
4 I usually wake up several times per night because of coughing
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routinely heralds the onset of a pulmonary exacerbation [8].
Change in cough severity in a clinical trial of a disease-
modifying therapy could provide an endpoint that reflects
salutary effects on underlying CF pathology and documents
improvements in patient well-being.
Subjective patient reporting of cough information in CF has
been collected through symptom or quality-of-life question-
naires [9]. However, such data may not be sufficient for
comprehensive evaluation of cough [10]. Objective cough
quantitation offers an additional or alternative approach. Efforts
to develop objective cough monitoring systems date to the
1950s but have intensified recently due to technological
advances [10]. Guidelines for objective cough assessment
now recommend using systems that have automated cough
recognition, can distinguish coughing from other sounds, permit
24-hour recording, and provide digital processing of cough
recordings; other desirable features include mobility, compact-
ness, and unobtrusiveness [11–13].
A device that meets these recommendations is the LifeShirt®
(hereafter “LifeShirt), which incorporates chest-wall, motion-
sensing transducers; electrocardiographic electrodes; a unidirec-
tional throat microphone; and a 3-axis accelerometer into a
lightweight, washable vest. The transducers are sewn in a
sinusoidal array onto the sleeveless, snugly fitting elastic shirt so
that they encircle the rib cage and abdomen at the level of the
nipples and umbilicus. The sensors are connected to a portable,
battery-powered signal-processing and recording unit with the
capacity for continuous data collection over≥24 h. The device is
the size of a palmtop computer and is attached to a belt (39).
Integrated input from the motion sensors and microphone
differentiates coughing from throat-clearing, sneezing, sighing,
or talking, and provides an analysis of the frequency, intensity,
and duration of cough. When compared to video/audio evalua-
tions of patients with chronic obstructive pulmonary disease,
mean LifeShirt cough rate values show a sensitivity of ~80%, a
specificity of N99%, and overall accuracy of N98% [14].
As a prelude to long-term clinical trials of an investigational
new drug (ataluren, PTC124®) [15], we performed this
observational feasibility study using the LifeShirt to evaluate
the pattern of coughing in patients with CF who had clinically
stable disease. The aims of the study were: (a) to assess the
feasibility of ambulatory cough assessment, (b) to quantify the
pattern and rate of coughing during wake and sleep, and (c) to
evaluate potential correlations between quantitative cough




The study was performed at a single CF center (Hadassah
Hebrew University Medical Center, Jerusalem, Israel). Patients
were ≥18 years of age. All patients had CF based on standard
diagnostic criteria [16]. Patients were clinically stable (ie, without
pulmonary exacerbation or upper respiratory tract infection); hadFEV1 values≥40% of predicted for age, gender, and height [17];
and had room-air oxygen saturation values of ≥92%. Clinical
stability was defined as the absence of: (a) ongoing acute illness
including acute upper or lower respiratory infections within
2 weeks before start of study treatment in this study, (b) history of
major complications of lung disease (including recent massive
hemoptysis or pneumothorax) within 2 months prior to start of
study treatment, (c) abnormalities on screening chest x-ray
suggesting clinically significant active pulmonary disease other
than CF, (d), significant abnormalities such as atelectasis or
pleural effusion which may be indicative of clinically significant
active pulmonary involvement secondary to CF, or (e) an ongoing
medical condition that, in the investigator's opinion, could impair
the assessment of study results. The institutional ethics committee
(Helsinki Committee, Hadassah Medical Organization, Jerusa-
lem) and the Israeli Ministry of Health approved the study
protocol. Participants provided signed informed consent.2.2. Study assessments
LifeShirt vests were provided to accommodate a range of
patient sizes. Patients were fitted with the vest in the clinic and
instructed to wear the vest for 24 hours at home during normal
activities of daily living. Continuously recorded, time-stamped
data were stored on a compact flash card housed within the
LifeShirt recorder. Upon return of the device to the clinic bymail,
data recordings were analyzed using device-specific software
(VivoLogic™). To document actual wake-sleep periods, body
position and breathing patterns were analyzed using predefined
algorithms that have been shown in sleep studies to demonstrate
good agreement with electroencephalography wake/sleep state
(92.3% of periods scored correctly).
Pulmonary function was assessed by spirometry before
cough quantitation. A symptom questionnaire was adminis-
tered. Because there is no established cough symptom
questionnaire [7], we developed a questionnaire considering
questions posed in past cough studies [18] and in symptom/
quality-of-life instruments used in CF [9]. Patients were asked
to select the description of daytime and nighttime coughing that
best matched their experience at the time of the quantitative
cough assessment (Table 1).
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Because this was an observational study, the sample size was
not based on a formal hypothesis; the target enrollment was ~20
patients. The cough algorithm defined a tussive blast (ie, a
forceful expiration against a closed or partially closed glottis) as
the simultaneous occurrence of (a) sound/vibration at the thyroid
cartilage detected by the throat microphone, and (b) high-
frequency vibration from the chest wall detected by motion
transducers. Based on prior experience [14], a cough was defined
as≥1 tussive blasts, each separated by b1 second and occurring
within the same expiratory breath. Cough rates were determined
by dividing the number of coughswithin a specified period (wake,
sleep, or overall) by the time spent wearing the LifeShirt during
that period. Individual cough intensity was characterized as the
amplitude of the cough signal measured in mV and individual
cough duration was described in milliseconds. Area under the
curve (AUC) represented an integration of cough intensity and
duration and was reported in mV•seconds. Differences between
values during wake and sleep periods were analyzed using
Wilcoxon signed-rank tests. Standard regression techniques were
used to evaluate correlations. Cough ratewas compared by gender
using an unpaired t-test.3. Results
3.1. Patient characteristics
The study enrolled 19 adult patients with established CF
(Table 2). Gender distribution was approximately even. Patients
generally had a severe CF phenotype, with the majority
showing chronic Pseudomonas airway infection as well asTable 2
Baseline Patient Characteristics.
Characteristic Value
Total patients studied, n 19
Age, median, years 26
[range] [19-57]
Gender, males:females, n 10:9
Sweat test, median, mEq/La 88
[range] [47–109]
TEPD total chloride conductance, median, mVb +0.7
[range] [−2.3–+9.3]
%-Predicted FEV1, median, kg 65
[range] [44-106]
Pseudomonas airway infection, n (%) 17 (89)
Exocrine pancreatic insufficiency, n (%) 17 (89)




Hypertonic saline 3 (16)
Fluticasone 3 (16)
Colistin 5 (26)
a Upper limit of normal = 40 mEq/L [19].
b Upper limit of normal = −5 mV [20].
Abbreviations: FEV1 = forced expiratory volume in 1 second, TEPD =
transepithelial potential difference.exocrine pancreatic insufficiency. Most patients were regularly
using inhaled medications.
3.2. Compliance, safety, and feasibility
All patients completed testing, wearing the device for a
median [range] of 24 [24-25] hours. Patients reported
occasional discomfort associated with neck pressure from the
throat microphone but reported no other device-related adverse
events. Clinic staff and patients reported no difficulty with
fitting the LifeShirt, use of the device, removal of the vest,
return of the device to the clinic, or uploading of data for
analysis.
3.3. Objective cough assessment
The LifeShirt documented that patients were awake for ~2/3
and asleep for ~1/3 of the 24-hour recording period (Table 3).
Patients coughed frequently, with a median of 643 coughs/day,
ranging from 324 coughs/day to 1569 coughs/day. Cough rate
was substantially higher during wake periods than sleep
periods. Chest physiotherapy was not performed on the days
that the LifeShirt was worn. Individual cough intensity and
duration, whether expressed as median or maximum values,
were also higher during waking than sleeping hours. Conse-
quently, the cough AUC was higher when patients were awake.
The pattern of coughing is illustrated by representative
cough rate data (Fig. 1) from 1 patient. Fig. 1A – depicting
coughs/minute during minutes with cough – illustrates the
typical waking pattern of incessant low-frequency coughing
punctuated by episodic paroxysms of high-frequency coughing.
Fig. 1B – depicting coughs/hour – demonstrates the typical
hour-to-hour variability in cough rate. The figure confirms that
almost all coughs occur during waking periods; coughing was
substantially less during both a nap period and a prolonged
overnight sleeping period.
To determine a minimum adequate recording period, cough
rates from the start of recording were assessed in successively
longer awake recording periods, incremented in 1-hour
intervals. These rates were correlated with total waking cough
rates during all awake recording for each patient (range of 12.4
to 20.1 hours). As indicated by progressively increasing
correlation coefficient values with increasingly longer data
collection time, recording 9 to 11 hours of waking cough data
accounted for 80% to 90% of the hour-to-hour variations in
overall hourly waking cough rate (Fig. 2).
3.4. Subjective cough assessment
One patient reported a subjective daytime cough score of 1
(“almost never have coughing during the day”), 13 patients
reported a subjective daytime cough score of 2 (“usually have a
few periods of coughing during the day”), and 5 reported a
subjective daytime cough score of 3(“usually have several
periods of coughing during the day”). Despite high objective
cough rates, no patient reported having a daytime cough score
of 4 (“frequent periods of coughing during the day”). Consistent
Table 3
Cough Data by Wake and Sleep Periods.
Parameter Wake Sleep Overall p-valuea
Time monitored, median, hours [range] 15 [12.4–20.1] 9 [4.5–11.9] 24.2 [23.8–25.3] –
Total coughs, median, n [range] 610 [323–1549] 18 [1–57] 643 [324–1569] –
Cough rate, median, coughs/hour [range] 41 [20–102] 2 [0.1–7] 27 [13–66] pb0.0001
Median peak cough intensity, median, mV [range] 1009 [422–2036] 431 [151–2918] 1086 [422–2005] p=0.11
Maximum peak cough intensity, median, mV [range] 3780 [2613–3784] 2556 [151–3780] 3780 [2613–3784] pb0.0001
Median individual cough duration, median, msec [range] 640 [350–770] 540 [140–820] 640 [340–760] p=0.0003
Maximum individual cough duration, median, msec [range] 1480 [1460–1480] 960 [140–1440] 1480 [1460–1480] pb0.0001
Median cough AUC, median, mV•sec [range] 214 [84–534] 80 [9–717] 220 [84–517] p=0.014
Maximum cough AUC, median, mV•sec [range] 3284 [875–4031] 441 [9–3785] 3784 [875–4031] pb0.0001
a Wilcoxon signed-rank test comparing wake vs sleep periods.
Abbreviation: AUC = area under the curve.
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17 patients indicated a nighttime cough score of 1 (“almost
never wake up because of coughing”), One patient indicated a
nighttime cough score of 2 (“usually wake up once per night
because of coughing”), and 1 patient indicated a nighttime
cough score of 3 (“usually wake up a few times per night
because of coughing”). Objective cough rate was not correlated
with subjective cough score (Fig. 3, A and B).
3.5. Correlations of objective cough to other patient variables
Objective cough rate tended to increase with worsening
pulmonary function (expressed by lower %-predicted FEV1)
(Fig. 3C) and with greater patient age (Fig. 3D). By contrast, no
effect of patient gender on cough rate was observed (Fig. 3E).
4. Discussion
The results of this evaluation of objective ambulatory 24-hour
cough quantitation confirm the relevance of cough as a
symptomatic manifestation of CF. The data indicate that
quantitative ambulatory cough assessment offers a safe and
practical method for documenting the extent of cough in patients
with CF and indicate that coughing occurs with a pattern
consistent with the underlying pathophysiology and natural
history of the disease. More generally, the results confirm the
utility of ambulatory cough assessment to assess respiratory
illnesses and illustrate the value of objective relative to subjective
methods in quantifying cough.
Our findings document that coughing is a pervasive problem
for patients with CF. Despite disease stability, our patients had
unremitting cough while awake; the lowest rate of awake cough
was 20 coughs/hour and could range to N100 coughs/hour. It is
remarkable that no patient showed a contiguous 1-hour awake
period without coughing. By contrast, healthy individuals
generally have b20 coughs in an entire day [18,21]. Consistent
with past data [18,22,23], we found that median cough rate was
higher (20-fold) when patients were awake than when they were
asleep. These data suggest an irritative source for the cough
reflex that is readily suppressible during sleep [24].
We believe these results provide a representative estimate of
cough rate in adults with CF. We included patients with a
typical range of pulmonary function, airway infection, andinhaled medication usage [1]. Veracity is supported by the
logical pattern of cough during wake and sleep, a pattern
previously observed in quantitative assessments [18,22,23].
Trends toward worsening of cough rate with greater airway
obstruction and disease duration are consistent with the natural
history of CF as assessed by FEV1 and age [4] and suggest that
daytime cough rate is a symptomatic marker of disease severity.
We limited our study to evaluation of adults. However,
objective cough assessment has been performed in children with
CF [22,25]. The LifeShirt is available in sizes suitable for
children and has been used to assess respiratory outcomes in
children as young as 2 years [26]. While cough rate is likely
lower in children than adults because of less severe disease,
prior quantitation documents frequent daytime coughing in
children with CF [22]. Thus, the early onset of inflammation
that is characteristic of the disease [1,2] may manifest as
coughing before FEV1 starts to decline [4], making cough rate a
potential outcome measure in clinical studies designed to
evaluate disease-modifying therapies in early CF. Objective
quantitative cough assessment may be particularly suitable for
young children because it is an effort-independent evaluation
requiring minimal patient cooperation.
At a practical level, the LifeShirt system meets criteria for
objective cough assessment [11–13]. Unlike previous inpatient
cough quantitation studies in CF [22,23,25], the ambulatory
nature of the device permits cough to be monitored in the
outpatient setting, enhancing the clinical relevance of the
results. Although neck pressure exerted by the throat micro-
phone could prove annoying, the otherwise unobtrusive nature
of the system encouraged patient acceptance. Feasibility may
have been enhanced because we fitted the patients with the
device in the clinic. However, the simplicity of the system
would allow patients to put on the device at home, and initiate
and complete recording on an alternate day (to avoid conflicts
with school or work activities) [26]. Of note, we asked patients
to forego percussive respiratory therapy for CF while wearing
the vest to avoid any potential damage or interference with
recording. Optionally, patients could temporarily remove the
system during percussive treatment. Use of a prepared mailer
proved useful for enhancing patient convenience in returning
the device.
The system we used illustrates that automation of data
recording, processing, and reporting is required for making
Fig. 1. Representative Distribution of Cough Rate by Wake and Sleep Periods.
Fig. 2. Correlation of Cough Rate by Length of Initial Awake Recording Period
with Overall Awake Cough Rate.
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strate that data-processing algorithms for assessing patient
wake-sleep status are critical for accurately enumerating cough
characteristics. These techniques avoid artifacts that would be
associated with averaging cough rates through intermittent
daytime sleep periods (ie, naps), calculating cough rates based
on arbitrary day-night divisions [18], or relying upon patient
diaries or quiet periods to define wake and sleep [25]. Clearly,
reporting only total coughs per day is not acceptable because of
the potential confounding effects of sleep on cough character-
istics. Considering the variability in the data while awake and
the minimal contribution of sleep periods to overall cough rate,
our results indicate that collecting data for N10 waking hours/
24-hour reporting period should generally provide an adequate
reflection of cough rate for periodic assessment in a clinical
trial.
Cough rate appears most appropriate as the principal measure
of cough severity; it is readily understood and improvements
would reflect benefit to patients. Peak cough intensity may have
value as an outcome, but may be less responsive to interventions
to reduce airway pathology than those to suppress cough reflex.Cough episode duration andAUCmay supplement other data, but
lack intuitive value as representations of cough severity. Based on
a previous method [14], we defined a cough as≥1 tussive blasts,
each separated by b1 second and occurring within the same
Fig. 3. Correlations of Objective Cough Rate with Other Patient Variables.
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terms of cough epochs (succession of coughs with b2 seconds
between individual coughs) [22], seconds of time spent coughing
per hour [23], or cough-seconds [25,27]. While any of these
methods is acceptable [28], these differences highlight the need to
consider cough definition when evaluating results across clinical
trials [28].
In our study, subjective reporting of cough severity comparing
daytime to nighttime was consistent with objective cough data, ie,
patients appropriately reported that they coughed more during the
day than during the night. However, when considering waking
cough, our results confirm the generally poor correlation between
objective and subjective cough assessment seen in other studies
[13,22,23,27,29]. Relying only upon patient reporting is
problematic. Patients accommodate to symptoms [30], and thus
tend to underreport all but themost intense episodes (eg, those thatare painful, are socially disruptive, or produce incontinence).
Patient assessments at frequent intervals (eg, hourly) are made
inaccurate by difficulties in defining cough, compliance failure,
and contamination bias. Substantial hour-to-hour variability in
cough rate (as we observed) makes self-reporting at longer
intervals (eg, daily or weekly) difficult because recall bias leads to
mental averaging of cough frequencies in some patients and
reporting of themost recent or severe events in others [31]. On the
other hand, patient reports do provide patient perception
information over longer periods than is feasible for objective
quantitation. Obtaining both objective and subjective information
periodically during a clinical trial seems optimal. In CF, 2 quality-
of-life instruments are available that include cough symptom
assessment [9].
Because of the one-time, observational characterization of
cough in this study, we could not generate reproducibility or
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in a therapeutic CF trial with monthly assessments performed
over 4 months indicates standard deviation for change (ΔSD) in
waking cough rate ranging from 14.7 to 19.5 coughs/hour
[Nilsen Miller – personal communication]. In prior studies
assessing cough rate quantitatively, responsiveness information
documents reductions in cough rate by 17 to 51% [23,32]. Thus,
targeting a 25% reduction in waking cough rate from 40 to
30 coughs/hour (mean decrease of 10 coughs/hour) with a
conservative ΔSD of 20 coughs/hour might be appropriate in
powering a trial of a new CF therapy using quantitative cough
assessment as an outcome measure [3].
Information regarding the subject's activity level during the
24-hour cough assessment is lacking in this study; the
relationship between cough frequency and activity may be
important to understand cough in this patient population.
Challenges associated with the use of the LifeShirt in large
clinical trials may include the cost of implementation and
patient adherence. Both problems may be limited by restricting
the frequency of cough assessment based upon knowledge of
the intervention being tested. In this study, adherence was
excellent with these motivated subjects.
For use in trials of new therapies, an ideal outcome measure
offers quantitative information regarding how a patient feels,
functions, or survives [33]. The measure should show a relevant
connection to the disease and its severity; be feasible in the
study population; provide accurate and reproducible informa-
tion; offer standardized simplicity in performance, analysis, and
reporting; and describe meaningful changes in a patient's
condition. The findings of this study indicate that quantitative
cough assessment using technically sophisticated ambulatory
devices like the LifeShirt may offer many of these attributes.
The data also show that the burden and the nature of chronic
coughing support cough characterization as a measure of
therapeutic effect in CF and other pulmonary chronic
respiratory conditions. Based on the results of this observational
study, we plan to perform objective and subjective cough
assessment in future long-term trials of ataluren in adult and
pediatric patients with CF.
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